Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
13 Mar 24
10-Q
2023 Q3
Quarterly report
3 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
8 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
Current reports
8-K
Entry into a Material Definitive Agreement
5 Apr 24
8-K
Departure of Directors or Certain Officers
18 Mar 24
8-K
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
13 Mar 24
8-K
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
3 Nov 23
8-K
Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 23
8-K
Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update
4 May 23
8-K
Regulation FD Disclosure
2 May 23
8-K
Regulation FD Disclosure
28 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
Registration and prospectus
S-8
Registration of securities for employees
14 Mar 24
S-3
Shelf registration
3 Nov 23
S-8
Registration of securities for employees
8 Mar 23
S-8
Registration of securities for employees
9 Mar 22
S-8
Registration of securities for employees
11 Mar 21
S-3
Shelf registration
9 Dec 20
424B5
Prospectus supplement for primary offering
23 Sep 20
424B5
Prospectus supplement for primary offering
23 Sep 20
S-3MEF
Registration of additional securities for an S-3
22 Sep 20
424B5
Prospectus supplement for primary offering
21 Sep 20
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 22
DEFA14A
Additional proxy soliciting materials
27 Apr 21
DEF 14A
Definitive proxy
27 Apr 21
DEFA14A
Additional proxy soliciting materials
23 Apr 20
DEF 14A
Definitive proxy
23 Apr 20
Other
EFFECT
Notice of effectiveness
15 Nov 23
CORRESP
Correspondence with SEC
9 Nov 23
UPLOAD
Letter from SEC
7 Nov 23
SEC STAFF
SEC staff action: Order
23 Mar 21
SEC STAFF
SEC staff action: Order
23 Feb 21
EFFECT
Notice of effectiveness
21 Dec 20
UPLOAD
Letter from SEC
16 Dec 20
CORRESP
Correspondence with SEC
15 Dec 20
EFFECT
Notice of effectiveness
27 May 20
CORRESP
Correspondence with SEC
21 May 20
Ownership
SC 13G
RA CAPITAL MANAGEMENT, L.P.
25 Apr 24
SC 13G
CITADEL ADVISORS LLC
22 Apr 24
SC 13G
CVI Investments, Inc.
9 Apr 24
SC 13G/A
ORBIMED ADVISORS LLC
14 Feb 24
4
Jesse Shefferman
23 Jan 24
4
Jathin Bandari
23 Jan 24
4
Jacqueline Zummo
23 Jan 24
4
Patrick Fabbio
23 Jan 24
4
Hannah Fry
23 Jan 24
4
Jesse Shefferman
12 Jan 24